Fermented Garlic Lettuce Powder and Cognitive Function in Adults With Mild Cognitive Impairment

NCT07321821 | Active Not Recruiting

• 1 other identifier: 11-2024-061
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

"This study aims to investigate the cognitive and psychological changes in adults with mild cognitive impairment (K-MoCA scores between 16 and 23) following daily consumption of fermented garlic lettuce powder for 2 months

Conditions

Mild Cognitive Impairment (MCI)

Keywords

Fermented Garlic Lettuce Powder; Mild Cognitive Impairment; Psychological Outcome; Randomized Controlled Trial

Outcome Measures

Primary Outcomes (1)

• K-MoCA

  The Korean version of the Montreal Cognitive Assessment (K-MoCA) is a cognitive screening tool with scores ranging from 0 to 30, with higher scores indicating better cognitive function. The outcome measure is the change in K-MoCA score.

  Assessments are performed at baseline and at 2 months.

Secondary Outcomes (10)

• SVLT

  Assessments are performed at baseline and at 2 months.

• KCWS

  Assessments are performed at baseline and at 2 months.

• RCFT

  Assessments are performed at baseline and at 2 months.

• DST

  Assessments are performed at baseline and at 2 months.

• COWAT

  Assessments are performed at baseline and at 2 months.

Study Arms (2)

Fermented Garlic Lettuce Powder

EXPERIMENTAL

Participants receive fermented garlic lettuce powder, administered orally as three tablets per day for 2 months (total of 180 tablets).

Dietary Supplement: Garlic Lettuce Fermented Powder

Placebo Tablet

PLACEBO COMPARATOR

Participants take 1 placebo tablet daily for 2 months, totaling 60 tablets

Other: Placebo

Interventions

Garlic Lettuce Fermented Powder DIETARY_SUPPLEMENT

The Garlic Lettuce Fermented Powder tablets (intervention group) are taken 3 tablets daily for 2 months, totaling 180 tablets

Fermented Garlic Lettuce Powder

Placebo OTHER

Participants take 1 placebo tablet daily for 2 months, totaling 60 tablets

Placebo Tablet

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults aged 19 years or older with K-MoCA scores between 16 and 23.
• Individuals with sufficient vision and hearing to participate in the study without difficulty.
• Participants who are currently taking medications or receiving treatments that may affect cognition and are able to maintain the same dosage and regimen throughout the study period.
• Individuals who voluntarily agree to participate in the study and provide written informed consent.

You may not qualify if:

• Individuals who have undergone vascular-related surgery within the past 6 months or gastrointestinal surgery that may affect absorption of the study product (excluding simple appendectomy or hernia repair).
• Individuals with a clinically significant history of hypersensitivity to medications or dietary supplements.
• Individuals with a history of alcohol or drug abuse.
• Individuals unable to communicate effectively.
• Individuals who have participated in more than two dietary supplement studies or clinical trials within the current year, or within the past 6 months.
• Individuals deemed unable to participate safely or effectively in the study by the investigator.

Sponsors & Collaborators

• Pusan National University Yangsan Hospital: lead

Study Sites (1)

Pusan National University Yangsan Hospital

Yangsan, Gyeongsangnam-do, South Korea

Location

MeSH Terms

Conditions

Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: except for one assessor who will have access to group assignments
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: Participants with mild cognitive impairment (K-MoCA scores 16-23) will be randomly assigned to either the intervention group receiving fermented garlic lettuce powder daily for 2 months or to a control group. Cognitive and psychological outcomes will be assessed at baseline and at the end of the 2-month intervention. Outcome assessors will be blinded to group allocation, and the study will be conducted as a single-center, investigator-initiated, parallel-group, randomized controlled trial.

Study Record Dates

• First Submitted: December 23, 2025
• First Posted: January 7, 2026
• Study Start: September 19, 2025
• Primary Completion: January 21, 2026
• Study Completion: January 21, 2026
• Last Updated: January 12, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)